load

Valenta was a Partner for the I Moscow City Congress of Pediatricians

Valenta was a Partner for the I Moscow City Congress of Pediatricians

24.11.2015

Within the event, Valenta organized «Domestic Innovations in Pediatrics. News of Flu and ARVI Therapy» satellite symposium

At the end of November, 2015, the I Moscow City Congress of Pediatricians «’Difficulties of Diagnosis’ in Pediatrics» was held and became a full-fledged communication platform of sharing experience and expertise for medical specialists working in a variety of fields (pediatricians, children’s endocrinologists, intensive care doctors, gynecologists, neonatologists, cardiologists, surgeons, urologists, psychologists, etc.), public healthcare professionals and leading specialists of Moscow children’s out-patient and polyclinic institutions and hospitals.

Valenta’s satellite symposium was devoted to the results of 2014-2015 epidemiologic season, outcomes of hospital flu monitoring, and the urgency of early implementation of antiviral therapy in children. Chairman of the symposium N.A. Geppe, MD, Professor, the Honored Doctor of the Russian Federation, Head of the Department of Children’s Diseases, Director of Clinic at I.M. Sechenov First MSMU, and L.V. Kolobukhina, MD, Professor at FSBI «N.F. Gamaleya FRCEM», Ministry of Health of Russia, Head of the Clinical Department of D.I.Ivanovsky Research Institute of Virology, presented their reports.

According to WHO, children make the majority of the age structure of flu and ARVI prevalence. Annually, every 3rd −5th child gets sick with flu. During the epidemiologic season of 2014-2015, almost all age groups were involved, while children aged between 0 and 14 years made about 60%1. The number of cases of children aged between 0 and 3 years hospitalized with confirmed ARVI diagnosis made 17%, and for children aged between 4 and 14 years this parameter was 39.1%2.

To address the disease more effectively, the algorithm of treatment should be represented with initial antiviral therapy within the first 36-48 hours of disease. This approach helps to reduce clinical symptoms and considerably decreases the risks of complications and death.

L.V. Kolobukhina, MD, Professor at FSBI «N.F. Gamaleya FRCEM», Ministry of Health of Russia, Head of the Clinical Department of D.I. Ivanovsky Research Institute of Virology: «Hospital monitoring during an epidemic season gives us opportunity to obtain data on quantitative and qualitative distribution of circulating A and B flu viruses in patients with ARVD, including serious forms. The question of early antiviral therapy implementation in children is extremely urgent. Immaturity of children’s immune system and a number of other factors determine the frequency and severity of ARVD in children. Treatment should be prescribed within the first 24-48 hours of disease, not waiting for the results of laboratory diagnostic tests. The antiviral therapy effectiveness should be assessed within the first 48 hours of treatment; and in the absence of positive dynamics, it is necessary to review the diagnosis with the purpose to detect a complicated development of the disease. The analysis of the course and outcomes of severe forms of flu for the period of 2009 to 2015 has shown the absence of appropriate antiviral therapy or administration of low effective medicines in all cases of the disease.»

  • 1 State report «About the Situation with Sanitary and Epidemiological Wellbeing of Population in the Russian Federation in 2014»
  • 2 According to Moscow IDCH No.1